Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief emeritus JCO GO, Board Member @UICC - chair #ATOMcoalition
Miami, FL
Joined November 2013
- Tweets60.1K
- Following40.4K
- Followers37.7K
- Likes85.2K
Pinned Tweet
My take on Galleri @WSJ @WSJopinion
“People differ in how they value earlier detection, uncertainty, diagnostic risk and out-of-pocket cost. Once regulators have judged the evidence sufficient for access, informed patients and their physicians should be able to examine these results and decide together. Approval need not mean universal screening. It should mean that government doesn’t substitute one national judgment for millions of individual decisions.”
@SylvesterCancer @asco @myESMO
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #WCLC26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgen
wsj.com/opinion/the-galleri-…
gilberto lopes retweeted
In budget fight, sheriff is ending top perk for Miami-Dade leaders: police drivers miamiherald.com/news/local/c…
gilberto lopes retweeted
Completely agree but I also think we need to identify patients who may benefit from this approach rather than a one-size-fits-all universal timing. Our study presented at ASCO 2026 suggests there may be scope for patient selection and identify those with intact circadian rhythms.
gilberto lopes retweeted
@SclcSMASHERS
@FDA
@LUNGevity
@lungoncdoc
@StephenVLiu
@HHorinouchi
@g_mountzios
@sands_jacob
@LauraAlderMD
@oncodaily
@OncoAlert
@Latinamd
@LuisPaz_Ares
@RManochakian
@LuisRaezMD
@triparnasen
@LaurenByersMD
@LungCancerEu
@alissajcooper
@BZhangMD
@NaglaAKarimMD
@Annechiangmd
@IASLC
@NCCN
@ASCO
#ESMO26
@larvol
@tribeMDUS
@sylvestercancer
@oncbrothers
@chinmay
@Jani_Chinmay
@colazagasti
@openmedicineHQ
@myesmo
@openmedkate
@openmedben
@chadinabhan
@YoungLungCancer
@OncodailyLung
@ClinicalLung
#LCSM
@LungPolicy
@dan_morgxen
@LAGurwitch
gilberto lopes retweeted
Congratulations @chadinabhan all the best for your new journey.
gilberto lopes retweeted
Are you a visual learner?
👉Global Oncology KOLs have shared infographics and slides across major tumor types to help prepare you for #ESMO26.
👉View the interactive tool, filter by tumor type, KOL, and trial name. 🤖Share the url with your AI tool for data discovery...
and perhaps build your own infographic creation!
👨⚕️👨🏽⚕️Featured Infographics Creators: @ChandrakanthMv, @ozdogan_md, @dr_yakupergun, @DrRishabhOnco, @glopesMD, @DrChoueiri
KOL Pulse hubs.ly/Q04B_B8N0
gilberto lopes retweeted
📣 Join us for LungÕ 2026 Virtual Global Congress on Lung Oncology coming up Nov 5th
👉🏽a great end of the year virtual review of thoracic oncology
👉🏽 with an international list of expert speakers focusing on early detection, precision diagnostics, multidisciplinary treatment and global onc.
Honored to cochair this congress with @glopesmd #lcsm
#lungcancer
oncodaily.com/lungo-2026-vir…
gilberto lopes retweeted
Congrats @cspramesh ! Very exciting! @WinshipAtEmory
gilberto lopes retweeted
Thrilled and honored to join @FoundationATCG as Chief Medical Officer. Grateful to the FMI leadership team for their trust and confidence and looking forward to this exciting new chapter and all we can accomplish together.
foundationmedicine.com/press…
gilberto lopes retweeted
WATCH: ESMO 2026 countdown to #1, INTerpath-001 (LBA1)
Intismeran autogene + pembrolizumab vs pembrolizumab in resected stage IIB–IV melanoma
• Presidential Symposium I, Sat Oct 24, 16:30 CEST / 7:30 am PT
• Presenter: Georgina V. Long
• Merck/Moderna (Aug 19, 2026): met RFS and DMFS at interim analysis; no HR released
• Phase 2b KEYNOTE-942 5-yr (n=157): RFS HR 0.510
No results until presentation. Intismeran is investigational. Plus 5 more late-breakers: AZUR-1, FOURLIGHT-1, KEYNOTE-C93, TroFuse-005, Krascendo 1.
oncologytube.com/esmo-2026-l…
#ESMO2026 #melanoma #immunotherapy
@ATarhiniMDPhD @DrSapnaPatel @evanlipson @TawbiHussein @zeyneperoglu @JenniferWargo @AnnaPavlick @RohitBanwar @AndreaCercek @marklewismd @ElenaElez @AfsanehBarzi @hoperugo @adityabardia @NeilVasan @KomalJhaveri @StephenVLiu @alexdrilon @JSabari @PatelOncology @JoelNealMD @ChristianRolfo @LeciaSequist @marinagarassino @DrSanjayPopat @CharuAggarwalMD @JhanelleGray @DrRaviSalgia @mljohnsonmd @JessicaJLinMD @TejasPatilMD @JordiRemon @MattGubensMD @DRCamidge @NarjustFlorezMD
gilberto lopes retweeted
@myESMO 2026: Day 1 Preview
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @PTarantinoMD | @ErikaHamilton9 | @stolaney1 | @pashtoonkasi | @ArndtVogel | @Erman_Akkus | @DrChoueiri | @DrYukselUrun | @neerajaiims
gilberto lopes retweeted
Many people have contacted me on #Miami Referendum 1.
This referendum is not “Backing the Blue”.
The only blue being backed are blue state & city policies that will add $800M debt to working families.
The money is there for first responders. Let’s find it.
NO on Resolution 1
gilberto lopes retweeted
Did you know Zócalo programs are on Soundcloud? Listen to them anytime, anywhere on topics ranging from politics and science to art and pop culture.soundcloud.com/zocalopublics…
Six years on the @UICC Board. Countless friendships. One shared mission.
Congratulations to CS Pramesh, Zainab Shinkafi-Bagudu and the new Board!
Grateful to colleagues and friends worldwide.
ALT Group photograph of UICC colleagues at an international meeting.
Leadership is service, and service continues through @ATOMCoalition, lung cancer and beyond.
#UICC
gilberto lopes retweeted
I couldn’t agree more but let’s leave the doors open for people who seek grants to run the IITs and address the question
gilberto lopes retweeted
VIDEO: Zipalertinib for active brain mets in EGFR exon 20 NSCLC? 30.2% intracranial ORR in REZILIENT2 Cohort C (data Oct 19, 2026) 🧠🫁
👉 oncologytube.com/zipalertini…
🔹 Phase 2b, single-arm: 43 RANO-BM–evaluable pts with active CNS mets (9 with LMD), EGFR ex20ins or uncommon EGFR
🔹 Intracranial DCR 72.1%; median iDoR 9.7 mo; iORR 37.5% with no prior EGFR TKI (n=24)
🔹 Grade ≥3 TRAEs 20.9%; paronychia 32.6%, diarrhea 25.6%
Prospective CNS data in patients usually kept out of trials. Investigational, not FDA approved; full poster at #ESMO2026.
@JuliaRotow @ZPiotrowskaMD @StephenVLiu @JoelNealMD @LeciaSequist @JessicaJLinMD @JSabari @PatelOncology @alexdrilon @JhanelleGray @TejasPatilMD @DRCamidge @CharuAggarwalMD @marinagarassino @DrSanjayPopat @JordiRemon @ChristianRolfo @NarjustFlorezMD @MattGubensMD @CoreyLangerMD @LaurenByersMD @ElaineShumMD @chulkimMD @DrRaviSalgia @AnaVManana @LovaSunMD @mljohnsonmd @HatimHusainMD @ShadiaJalal @LuisRaezMD @drtahuahua @EdKimMD @ManuelDomine @KHigginsMD @charlesrudin
#LCSM #NSCLC #EGFR #Exon20 #BrainMets #LungCancer
gilberto lopes retweeted
Gilberto de Lima Lopes Jr. came of age in the shadow of Brazil's dictatorship. This year, he casts his first ballot as a U.S. citizen. Read about what he's learned about the value of his vote:
zps.la/4BzCuA2
Agree! Here is the piece I wrote about it back in May.
connection.asco.org/do/looki…
🚨⭐️⭐️⭐️Just Published 👉Right in Time for @myESMO #ESMO26👉 Pleased to share our new paper in JCO @JCO_ASCO @ASCO
👉⭐️ “Time-of-Day Immunotherapy: Why the Field Still Needs Randomized Evidence.”
⭐️⭐️⭐️OPEN ACESS+ FREE for all to read & comment
⭐️👉@Timothee_MD , @Alfdoc2 & I set out to compare our views on RCTs. We AGREED on one point immediately 👉 THAT this question deserves a definitive answer
👉Retrospective data suggested that the time of day an immunotherapy infusion is given may affect outcomes. The first randomized phase III trial that appeared to confirm this has since been retracted, and the question is open again.
👉Our view: the optimal timing of immunotherapy remains unsettled, and robust randomized evidence is the only responsible way forward @OncoAlert @oncodaily ascopubs.org/doi/10.1200/JCO…
